

CME

Cardiac Troponin After Percutaneous Coronary Intervention and 1-Year Mortality in Non–ST-Segment Elevation Acute Coronary Syndrome Using Systematic Evaluation of Biomarker Trends

Pierluigi Tricoci, MD, MHS, PhD,* Sergio Leonardi, MD, MHS,† Jennifer White, MS,* Harvey D. White, MB, CHB, DSc,‡ Paul W. Armstrong, MD,§ Gilles Montalescot, MD,|| Robert P. Giugliano, MD, SM,¶ C. Michael Gibson, MD,# Frans Van de Werf, MD,** Robert M. Califf, MD,* Robert A. Harrington, MD,†† Eugene Braunwald, MD,¶¶ Kenneth W. Mahaffey, MD,* L. Kristin Newby, MD, MHS*

Durham, North Carolina; Pavia, Italy, Auckland, New Zealand; Edmonton, Alberta, Canada; Paris, France; Boston, Massachusetts; Leuven, Belgium; and Stanford, California

JACC JOURNAL CME

This article has been selected as the month's *JACC* Journal CME activity.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME Certificate

To obtain credit for *JACC* CME, you must:

1. Be an ACC member or *JACC* subscriber.
2. Carefully read the CME-designated article available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME Objective for This Article: At the end of this activity, the learner should be able to review cardiac troponin (cTn) trends during non–ST-segment elevation acute coronary syndrome (NSTEMI/ACS) in patients undergoing percutaneous coronary intervention (PCI) in EARLY ACS and SYNERGY and the relationship between post-PCI cTn and mortality.

CME Editor Disclosure: *JACC* CME Editor Ajit Raisinghani, MD, FACC, reports that he has no financial relationships or interests to disclose.

Author Disclosures: Dr. Tricoci has received grant support and consulting fees from Schering-Plough and Merck & Co., Inc. Dr. White has received research grants from sanofi-aventis, Eli Lilly, The Medicines Company, National Institutes of Health, Pfizer, Roche, Johnson & Johnson, Schering-Plough, Merck & Co., Inc., Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Pharma Development, and Bristol-Myers Squibb; and consulting fees from Regado Biosciences. Dr. Armstrong has received consulting fees from Merck Frosst Canada Ltd.; and research support from Schering-Plough and Merck & Co., Inc. Dr. Montalescot has received consulting and lecture fees from Schering-Plough and Merck & Co., Inc.; and received support from Bayer HealthCare, Bristol-Myers Squibb, Boehringer-Ingelheim, Duke Institute, Europa, GlaxoSmithKline, Iroko, Lead-Up, Novartis, Springer, TIMI Group, WebMD, Wolters, AstraZeneca, Biotronik, Eli Lilly, The Medicines Company, Medtronic,

From the *Duke Clinical Research Institute, Durham, North Carolina; †Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy; ‡Green Lane Cardiovascular Service, Auckland, New Zealand; §University of Alberta, Edmonton, Alberta, Canada; ||Cardiology Department, La Pitié-Salpêtrière Hospital, Paris, France; ¶Brigham and Women's Hospital, Boston, Massachusetts; #Beth Israel Deaconess Medical Center,

Boston, Massachusetts; **Division of Cardiology, Catholic University of Leuven, Leuven, Belgium; and the ††Department of Medicine, Stanford University, Stanford, California. The SYNERGY study was supported by Aventis Inc. The EARLY ACS trial was funded by Schering-Plough Corporation (now Merck & Co., Inc.). These analyses were funded by research grant support from Merck & Co., Inc. Dr. Tricoci

Menarini, Roche, sanofi-aventis, Abbott Vascular, Fédération Française de Cardiologie, Fondation de France, Nanospheres, Pfizer Inc., Stentys, and Société Française de Cardiologie. Dr. Giugliano has reported that he has received research support and honoraria for continuing medical education lectures from Schering-Plough and Merck & Co., Inc.; and has served on the advisory board of Schering-Plough/Merck & Co., Inc. Dr. Gibson has received research support and consulting fees from Schering-Plough and Merck & Co., Inc.; received research support paid to his institution from Angel Medical Corporation, Atrium Medical Systems, Bayer HealthCare, Genentech, Inc., Ikaria, Inc., Janssen Pharmaceuticals, Johnson & Johnson, Lantheus Medical Imaging, Merck & Co., Inc., Portola Pharmaceuticals, Roche Diagnostics, sanofi-aventis, Stealth Peptides, Inc., St. Jude Medical, Volcano Corp., Walk Vascular; has peer-to-peer communications with Daiichi Sankyo, Eli Lilly, and The Medicines Company; has received consulting fees from and served on advisory boards of AstraZeneca, Baxter Healthcare, Bayer HealthCare (fees paid to institution), Boston Clinical Research Institute, Bristol-Myers Squibb, Cardiovascular Research Foundation, Consensus Medical Communications, CSI Behring, Cytosol Therapeutics, Daiichi Sankyo, Eli Lilly, Exeter Group, Ischemix, Inc., Janssen Pharmaceuticals (fees paid to institution), Johnson & Johnson (fees paid to institution), Merck & Co., Inc., Ortho McNeil (fees paid to institution), Regado Biosciences, Inc., sanofi-aventis, St. Jude Medical, The Medicines Company; and he has received royalties as a contributor from UpToDate in Cardiovascular Medicine. Dr. Van de Werf has received research support, advisory board, and speaker fees from Schering-Plough and Merck & Co., Inc. Dr. Califf has received consulting fees from Bayer HealthCare, Bristol-Myers Squibb, CV Sight, LLC, DSI-Lilly, Gambro, Heart.org, Janssen R&D, LLC, Kowa, Novartis, Pfizer Inc., Regeneron, and Roche Diagnostics; has equity in Merck & Co., Inc., and Portola Pharmaceuticals; and has received research grants from Bristol-Myers Squibb Foundation, Novartis, Amylin, Merck & Co., Inc., Schering-Plough Research Institute, Scios, Johnson & Johnson, and Eli Lilly. Dr. Harrington has received research grants from Merck & Co., Inc., sanofi-aventis, Daiichi Sankyo, GlaxoSmithKline, The Medicines Company, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Portola Pharmaceuticals, and Regado Biosciences, Inc.;

has received consulting fees from Baxter Healthcare, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Science, Merck & Co., Inc., Orexigen; and has received educational programming fees from WebMD. Dr. Braunwald has served as chair of the TIMI Study Group at the Brigham and Women's Hospital, which receives (or has received) grant support for the TIMI Study Group from the following pharmaceutical companies: Eli Lilly, Merck & Co., Inc., Schering-Plough Research Institute, and Daiichi-Sankyo; he has participated in symposia/advisory board meetings/consultancies, for which he receives honoraria and reimbursement of travel-related expenses, for Daiichi-Sankyo, Eli Lilly, and Schering-Plough; and has provided uncompensated consulting and symposia lectures for Merck & Co., Inc.. Dr. Mahaffey has received support from Abbott Vascular, Adolor, Amgen, Amylin, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb, Cordis Corp., Daiichi Sankyo, Dialouges, Edwards Lifesciences, Eli Lilly, Elsevier, Forest, Genentech, GlaxoSmithKline, Gilead Science, Guidant Corporation, Haemonetics, Ikaria, Cubist, John Hopkins University, Johnson & Johnson, Luitpold, Medtronic, Merck & Co., Inc., Novartis, Orexigen, Ortho/McNeill, Pfizer Inc., Polymedix, Portola Pharmaceuticals, Pozen, Regado Biosciences, Roche Diagnostic, sanofi-aventis, Schering-Plough, South East Area Health Education Center, Springer, St. Jude Medical, SunPharma, and The Medicines Company. Dr. Newby has received consulting fees from Daiichi-Sankyo, Genentech, Novartis, Roche Diagnostics, Janssen Pharmaceuticals, Navigant, and DSI-Lilly; and has received research grant support from Amylin, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Murdock Study, and the National Heart, Lung, and Blood Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz)

CME Term of Approval:

Issue date: July 16, 2013

Expiration date: July 15, 2014

has received grant support and consulting fees from Schering-Plough and Merck & Co., Inc. Dr. White has received research grants from sanofi-aventis, Eli Lilly, The Medicines Company, National Institutes of Health, Pfizer, Roche, Johnson & Johnson, Schering-Plough, Merck & Co., Inc., Sharpe & Dohme, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Pharma Development, and Bristol-Myers Squibb; and consulting fees from Regado Biosciences. Dr. Armstrong has received consulting fees from Merck Frosst Canada Ltd.; and research support from Schering-Plough and Merck & Co., Inc. Dr. Montalescot has received consulting and lecture fees from Schering-Plough and Merck & Co., Inc.; and received support from Bayer HealthCare, Bristol-Myers Squibb, Boehringer-Ingelheim, Duke Institute, Europa, GlaxoSmithKline, Iroko, Lead-Up, Novartis, Springer, TIMI Group, WebMD, Wolters, AstraZeneca, Biotronik, Eli Lilly, The Medicines Company, Medtronic, Menarini, Roche, sanofi-aventis, Abbott Vascular, Fédération Française de Cardiologie, Fondation de France, Nanospheres, Pfizer Inc., Stentys, and Société Française de Cardiologie. Dr. Giugliano has reported that he has received research support and honoraria for continuing medical education lectures from Schering-Plough and Merck & Co., Inc.; and has served on the advisory board of Schering-Plough/Merck & Co., Inc. Dr. Gibson has received research support and consulting fees from Schering-Plough and Merck & Co., Inc.; received research support paid to his institution from Angel Medical Corporation, Atrium Medical Systems, Bayer HealthCare,

Genentech, Inc., Ikaria, Inc., Janssen Pharmaceuticals, Johnson & Johnson, Lantheus Medical Imaging, Merck & Co., Inc., Portola Pharmaceuticals, Roche Diagnostics, sanofi-aventis, Stealth Peptides, Inc., St. Jude Medical, Volcano Corp., Walk Vascular; has peer-to-peer communications with Daiichi Sankyo, Eli Lilly, and The Medicines Company; has received consulting fees from and served on advisory boards of AstraZeneca, Baxter Healthcare, Bayer HealthCare (fees paid to institution), Boston Clinical Research Institute, Bristol-Myers Squibb, Cardiovascular Research Foundation, Consensus Medical Communications, CSI Behring, Cytosol Therapeutics, Daiichi Sankyo, Eli Lilly, Exeter Group, Ischemix, Inc., Janssen Pharmaceuticals (fees paid to institution), Johnson & Johnson (fees paid to institution), Merck & Co., Inc., Ortho McNeil (fees paid to institution), Regado Biosciences, Inc., sanofi-aventis, St. Jude Medical, The Medicines Company; and he has received royalties as a contributor from UpToDate in Cardiovascular Medicine. Dr. Van de Werf has received research support, advisory board, and speaker fees from Schering-Plough and Merck & Co., Inc. Dr. Califf has received consulting fees from Bayer HealthCare, Bristol-Myers Squibb, CV Sight, LLC, DSI-Lilly, Gambro, Heart.org, Janssen R&D, LLC, Kowa, Novartis, Pfizer Inc., Regeneron, and Roche Diagnostics; has equity in Merck & Co., Inc., and Portola Pharmaceuticals; and has received research grants from Bristol-Myers Squibb Foundation, Novartis, Amylin, Merck & Co., Inc., Schering-Plough Research Institute, Scios, Johnson & Johnson, and Eli Lilly. Dr. Harrington has received research

Download English Version:

<https://daneshyari.com/en/article/5983461>

Download Persian Version:

<https://daneshyari.com/article/5983461>

[Daneshyari.com](https://daneshyari.com)